Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
7.7
4.3
Journals
Pharmaceuticals
Sections
Feature Review Collection in Medicinal Chemistry
share announcement

Feature Review Collection in Medicinal Chemistry

A topical collection in Pharmaceuticals (ISSN 1424-8247). This collection belongs to the section "Medicinal Chemistry".

Viewed by 987

Editors

Dr. Alessandra Ammazzalorso

E-Mail Website
Collection Editor
Department of Pharmacy, “G. d’Annunzio” University of Chieti-Pescara, Chieti, Italy
Interests: medicinal chemistry; drug discovery; aromatase inhibitors; PPAR ligands; anticancer agents
Special Issues, Collections and Topics in MDPI journals
Dr. Luís M. T. Frija

E-Mail Website
Collection Editor
Centro de Química Estrutural, Instituto Superior Técnico—Universidade de Lisboa, Lisbon, Portugal
Interests: organic chemistry; tetrazoles, thiazoles and thiadiazoles; nitrogen ligands; organocatalysis; metal catalysis; selective chelators for metals on biological medium; leads for cancer chemotherapy
Special Issues, Collections and Topics in MDPI journals

Topical Collection Information

Dear Colleagues,

It is a great pleasure to present this novel Topical Collection in Pharmaceuticals. The “Feature Review Collection in Medicinal Chemistry” aims to collect significant contributions on all aspects of medicinal chemistry, providing a useful platform for all researchers involved in this discipline.

Relevant topics in this collection include rational design, synthesis, and structure–activity relationship studies of compounds of pharmaceutical interest, including both synthetic and natural compounds. Studies on novel synthetic routes for drug candidates are welcome, as are optimization methods, pharmacokinetic evaluations, and drug metabolism studies.

The identification and validation of novel drug targets, the description of novel screening methodologies, and the application of machine learning and modern computational techniques in drug discovery are also relevant topics.

The scope of these feature reviews covers the wide landscape of bioactive compounds, comprising both small organic molecules, and more sophisticated approaches, such as biotechnological drugs. Medicinal chemistry advancements in biotechnological drugs, as antibody-drug conjugates, peptide-drug conjugates, and engineered cytokines, represent significant topics that are highly welcomed.  

Submissions to this Topical Collection need to include a cover letter stating the novelty of the review article in comparison to related reviews published in the literature.

Dr. Alessandra Ammazzalorso
Dr. Luís M. T. Frija
Collection Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the collection website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceuticals is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • drug discovery
  • structure–activity relationships
  • synthesis
  • natural compounds
  • lead optimization
  • enzyme inhibitors
  • drug targets
  • biotechnological drugs

Published Papers (2 papers)

Download All Papers

2025

33 pages, 6650 KiB  
Review
M. avium Complex Pulmonary Infections: Therapeutic Obstacles and Progress in Drug Development
by Elise Si Ahmed Charrier, Alexandra Dassonville-Klimpt, Claire Andréjak and Pascal Sonnet
Pharmaceuticals 2025, 18(6), 891; https://doi.org/10.3390/ph18060891 (registering DOI) - 13 Jun 2025
Viewed by 150
Abstract
Worldwide, several million people are infected with mycobacteria such as Mycobacterium tuberculosis (M. tb) or non-tuberculous mycobacteria (NTM). In 2023, 10.8 million cases and 1.25 million deaths due to M. tb were recorded. In Europe and North America, the emergence of [...] Read more.
Worldwide, several million people are infected with mycobacteria such as Mycobacterium tuberculosis (M. tb) or non-tuberculous mycobacteria (NTM). In 2023, 10.8 million cases and 1.25 million deaths due to M. tb were recorded. In Europe and North America, the emergence of NTM is tending to outstrip that of M. tb. Among pulmonary NTM, Mycobacterium avium complex (MAC) is the most common, accounting for 80% of NTM infections. First-line treatment requires the combination of at least three antibiotics over a long period and with different mechanisms of action to limit cross-resistance. The challenge is to discover more effective new anti-MAC molecules to reduce the duration of treatment and to overcome resistant strains. The aim of this review is to present an overview of the challenges posed by MAC infection such as side effects, reinfections and resistance mechanisms. The latest therapeutic options such as the optimized combination therapy, drug repurposing and the development of new formulations, as well as new anti-MAC compounds currently in (pre)clinical trials will also be discussed. Full article
►▼ Show Figures

Figure 1

25 pages, 5895 KiB  
Review
Exploring the Potential of s-Triazine Derivatives as Novel Antifungal Agents: A Review
by Haoyan Liao, Menglu Liu, Mengyuan Wang, Dazhi Zhang, Yumeng Hao and Fei Xie
Pharmaceuticals 2025, 18(5), 690; https://doi.org/10.3390/ph18050690 - 7 May 2025
Viewed by 598
Abstract
The growing incidence and prevalence of invasive fungal infections (IFIs) and the emergence of antimicrobial resistance compound clinical antifungal therapies. Given the significant threat posed by IFIs and the limits of the current antifungal agents, the search for novel, effective therapeutic options remains [...] Read more.
The growing incidence and prevalence of invasive fungal infections (IFIs) and the emergence of antimicrobial resistance compound clinical antifungal therapies. Given the significant threat posed by IFIs and the limits of the current antifungal agents, the search for novel, effective therapeutic options remains a compelling area of antifungal drug discovery. The s-triazine (1,3,5-triazine) scaffold, renowned for its structural versatility, ease of functionalization, and diverse biological profiles, has been extensively studied in medical chemistry. Driven by this privileged structure, several s-triazine derivatives have been synthesized through molecular hybridization and screened for their antifungal activities. Some of them demonstrated potent efficacy against pathogenic fungi, including Candida, Cryptococcus, and Aspergillus species. Structure–activity relationship (SAR) studies are also discussed whenever possible, underlying the essential substituents for their antifungal effect. This review provides a summary of recent advancements (2014–2024) in the development of antifungal agents featuring the s-triazine scaffold and highlights the antifungal activity of s-triazine derivatives, aiming to prompt further progress in this field. Full article
►▼ Show Figures

Graphical abstract

Back to TopTop